TAE Life Sciences
  • ABOUT US
    • WE ARE TAE LIFE SCIENCES
    • BOARD OF DIRECTORS
    • MANAGEMENT TEAM
  • ABOUT BNCT
  • OUR NEUTRON SOURCE
  • PARTNERS
  • NEWS
  • CAREERS
  • CONTACT
  • ABOUT US
    • WE ARE TAE LIFE SCIENCES
    • BOARD OF DIRECTORS
    • MANAGEMENT TEAM
  • ABOUT BNCT
  • OUR NEUTRON SOURCE
  • PARTNERS
  • NEWS
  • CAREERS
  • CONTACT

News

Home > News
TAE Life Sciences Press Release
March 12, 2018

TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A Funding

March 2018 | PR Newswire| Read Now

TAE Life Sciences is the first to license TAE Technologies’ accelerator-based neutron beam technology for clinical investigation of Boron Neutron Capture Therapy (BNCT).

Newer
12
Older
TAE Life Sciences
  • ABOUT US
  • ABOUT BNCT
  • OUR NEUTRON SOURCE
  • PARTNERS
  • CONTACT

Copyright ©2018 TAE Life Sciences. All Rights Reserved.

* The device being developed by TAE Life Sciences is for investigational use only and has not been approved for sale or commercial use.